Cory Christiansen1, Charity Moore, Margaret Schenkman, Benzi Kluger, Wendy Kohrt, Anthony Delitto, Brian Berman, Deborah Hall, Deborah Josbeno, Cynthia Poon, Julie Robichaud, Toby Wellington, Samay Jain, Cynthia Comella, Daniel Corcos, Ed Melanson. 1. Department of Physical Medicine and Rehabilitation (C.C., M.S.), Department of Neurology (B.K., B.B.), Division of Geriatric Medicine (W.K., T.W., E.M.), and Division of Endocrinology, Metabolism, and Diabetes (E.M.), University of Colorado School of Medicine, Aurora, Colorado; Geriatric Research Education and Clinical Center, VA Eastern Colorado Healthcare System, Denver, Colorado (C.C.); Dickson Advanced Analytics, Carolinas HealthCare System, Charlotte, North Carolina (C.M.); School of Health and Rehabilitation Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania (A.D., D.J.); Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois (D.H., C.C.); Department of Physical Therapy and Human Movement Sciences, Northwestern University, Chicago, Illinois (C.P., D.C.); Department of Physical Therapy, University of Illinois at Chicago, Chicago Illinois (J.R.); and Department of Neurology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (S.J.).
Abstract
BACKGROUND AND PURPOSE: Objective ambulatory activity during daily living has not been characterized for people with Parkinson disease prior to initiation of dopaminergic medication. Our goal was to characterize ambulatory activity based on average daily step count and examine determinants of step count in nonexercising people with de novo Parkinson disease. METHODS: We analyzed baseline data from a randomized controlled trial, which excluded people performing regular endurance exercise. Of 128 eligible participants (mean ± SD = 64.3 ± 8.6 years), 113 had complete accelerometer data, which were used to determine daily step count. Multiple linear regression was used to identify factors associated with average daily step count over 10 days. Candidate explanatory variable categories were (1) demographics/anthropometrics, (2) Parkinson disease characteristics, (3) motor symptom severity, (4) nonmotor and behavioral characteristics, (5) comorbidities, and (6) cardiorespiratory fitness. RESULTS: Average daily step count was 5362 ± 2890 steps per day. Five factors explained 24% of daily step count variability, with higher step count associated with higher cardiorespiratory fitness (10%), no fear/worry of falling (5%), lower motor severity examination score (4%), more recent time since Parkinson disease diagnosis (3%), and the presence of a cardiovascular condition (2%). DISCUSSION AND CONCLUSIONS: Daily step count in nonexercising people recruited for this intervention trial with de novo Parkinson disease approached sedentary lifestyle levels. Further study is warranted for elucidating factors explaining ambulatory activity, particularly cardiorespiratory fitness, and fear/worry of falling. Clinicians should consider the costs and benefits of exercise and activity behavior interventions immediately after diagnosis of Parkinson disease to attenuate the health consequences of low daily step count.Video Abstract available for more insights from the authors (see Video, Supplemental Digital Content 1, http://links.lww.com/JNPT/A170).
RCT Entities:
BACKGROUND AND PURPOSE: Objective ambulatory activity during daily living has not been characterized for people with Parkinson disease prior to initiation of dopaminergic medication. Our goal was to characterize ambulatory activity based on average daily step count and examine determinants of step count in nonexercising people with de novo Parkinson disease. METHODS: We analyzed baseline data from a randomized controlled trial, which excluded people performing regular endurance exercise. Of 128 eligible participants (mean ± SD = 64.3 ± 8.6 years), 113 had complete accelerometer data, which were used to determine daily step count. Multiple linear regression was used to identify factors associated with average daily step count over 10 days. Candidate explanatory variable categories were (1) demographics/anthropometrics, (2) Parkinson disease characteristics, (3) motor symptom severity, (4) nonmotor and behavioral characteristics, (5) comorbidities, and (6) cardiorespiratory fitness. RESULTS: Average daily step count was 5362 ± 2890 steps per day. Five factors explained 24% of daily step count variability, with higher step count associated with higher cardiorespiratory fitness (10%), no fear/worry of falling (5%), lower motor severity examination score (4%), more recent time since Parkinson disease diagnosis (3%), and the presence of a cardiovascular condition (2%). DISCUSSION AND CONCLUSIONS: Daily step count in nonexercising people recruited for this intervention trial with de novo Parkinson disease approached sedentary lifestyle levels. Further study is warranted for elucidating factors explaining ambulatory activity, particularly cardiorespiratory fitness, and fear/worry of falling. Clinicians should consider the costs and benefits of exercise and activity behavior interventions immediately after diagnosis of Parkinson disease to attenuate the health consequences of low daily step count.Video Abstract available for more insights from the authors (see Video, Supplemental Digital Content 1, http://links.lww.com/JNPT/A170).
Authors: Christopher G Goetz; Werner Poewe; Olivier Rascol; Cristina Sampaio; Glenn T Stebbins; Carl Counsell; Nir Giladi; Robert G Holloway; Charity G Moore; Gregor K Wenning; Melvin D Yahr; Lisa Seidl Journal: Mov Disord Date: 2004-09 Impact factor: 10.338
Authors: James T Cavanaugh; Terry D Ellis; Gammon M Earhart; Matthew P Ford; K Bo Foreman; Leland E Dibble Journal: J Neurol Phys Ther Date: 2012-06 Impact factor: 3.649
Authors: Marjolein A van der Marck; Heleen C Dicke; Ergun Y Uc; Zippora H A Kentin; George F Borm; Bastiaan R Bloem; Sebastiaan Overeem; Marten Munneke Journal: Parkinsonism Relat Disord Date: 2011-11-18 Impact factor: 4.891
Authors: Patricia Katz; Mary Margaretten; Laura Trupin; Gabriela Schmajuk; Jinoos Yazdany; Edward Yelin Journal: Arthritis Care Res (Hoboken) Date: 2016-01 Impact factor: 4.794
Authors: E Havlikova; J Rosenberger; I Nagyova; B Middel; T Dubayova; Z Gdovinova; J P van Dijk; J W Groothoff Journal: Eur J Neurol Date: 2008-03-05 Impact factor: 6.089
Authors: Margaret Schenkman; Charity G Moore; Wendy M Kohrt; Deborah A Hall; Anthony Delitto; Cynthia L Comella; Deborah A Josbeno; Cory L Christiansen; Brian D Berman; Benzi M Kluger; Edward L Melanson; Samay Jain; Julie A Robichaud; Cynthia Poon; Daniel M Corcos Journal: JAMA Neurol Date: 2018-02-01 Impact factor: 18.302
Authors: Terry D Ellis; Cristina Colón-Semenza; Tamara R DeAngelis; Cathi A Thomas; Marie-Hélène Saint Hilaire; Gammon M Earhart; Leland E Dibble Journal: Semin Neurol Date: 2021-03-19 Impact factor: 3.420
Authors: Filipe Oliveira de Almeida; Vagner Santana; Daniel M Corcos; Carlos Ugrinowitsch; Carla Silva-Batista Journal: Sports Med Date: 2022-02-03 Impact factor: 11.928